Wave Life Sciences Ltd

Stock Chart, Company Information, and Scan Results

$7.92(as of Sep 4, 1:38 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Wave Life Sciences Ltd Company Information, Fundamentals, and Technical Indicators

Stock Price$7.92
Ticker SymbolWVE
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees287
CountyUSA
Market Cap$1,531.8M
EBIDTA-139.9M
10-Day Moving Average9.65
P/E Ratio-10.10
20-Day Moving Average9.23
Forward P/E Ratio0.00
50-Day Moving Average8.32
Earnings per Share-0.80
200-Day Moving Average9.57
Profit Margin-580.17%
RSI37.04
Shares Outstanding159.2M
ATR0.66
52-Week High16.74
Volume10,839,358
52-Week Low5.04
Most Recent Support Level9.26
Book Value147.1M
Most Recent Resistance Level10.45
P/B Ratio8.92
Upper Keltner10.71
P/S Ratio13.96
Lower Keltner7.75
Debt-to-Equity Ratio10.71
Next Earnings Date11/06/2025
Cash Surplus121.1M
Next Ex-Dividend DateUnknown

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

Wave Life Sciences Ltd In Our Stock Scanner

As of Sep 04, 2025
example chart graphic
Scan Name: Momentum StocksScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Unusual VolumeScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Undervalued StocksScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Undervalued Blue ChipsScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.